Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd > Update

<< Previous

Bullboard Posts

Next >>

Comment by duchebaggieon Oct 31, 2012 4:14pm

152 Views

Post# 20546775

RE: RE: RE: RE: RE: Update

Alright, thanks for the update. I think that it will be a no-brainer however.

Now if they could loosen up the capping in the new estimate and update the smaller deposits at the same time, it could be a game changer here, with possibly around 3M oz. I'm not going anywhere until July 5th 2013.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario